Traitement par daratumumab (anticorps anti-CD38), une avancée thérapeutique majeure pour les patients atteints de myélome multiple mais une complexité pour les biologistes

Abstract

AbstractSurvival in patients with multiple myeloma dramatically improved over the past decades thanks to new targeted therapies. Among the latter, daratumumab, a monoclonal antibody targeting cells expressing CD38, a marker highly expressed on plasma cells, is now offered as a first-line treatment. Due to its characteristic, this therapy is responsible for several analytical interferences that we illustrate in the presented case. It is essential that the biologist masters all these interferences which can influence both the monitoring of the disease (protein electrophoresis assay, flow cytometry) and the transfusion safety of these patients.